NAP in Combination With Docetaxel Following Obinutuzumab Pretreatment in Subjects With Checkpoint Inhibitor Pretreated Advanced or Metastatic NSCLC

Completed · Phase 2

Conditions studied: Non-small Cell Lung Cancer

In brief

Phase 2a Open-Label, Multicenter Trial of Naptumomab Estafenatox (NAP), following Obinutuzumab Pretreatment, on Days -13 and -12. NAP will be administered on Days 1-4 of treatment cycles 1-6, followed by docetaxel on Day 5. Starting cycle 7, NAP at a higher dose will be administered on Day 1 only and docetaxel on Day 2, in 21 days treatment cycles. When NAP is administered as monotherapy and not earlier than cycle 7, NAP will be administered on Day 1 only and cycles will be of 28 days treatment cycle.

Key facts

Study ID

NCT04880863

Run by

NeoTX Therapeutics Ltd.

People needed

38

Starts

2021-10-26

Expected to finish

2024-01-30

Last updated by the study team

2025-03-03

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• NeoTX - 10307 — Daphne, Alabama, United States
• NeoTX - 10302 — Scottsdale, Arizona, United States
• NeoTX - 10303 — Tucson, Arizona, United States
• NeoTX - 10306 — Lone Tree, Colorado, United States
• NeoTX - 10304 — Minneapolis, Minnesota, United States
• NeoTX - 10100 — Morristown, New Jersey, United States
• NeoTX - 10308 — Austin, Texas, United States
• NeoTX - 10309 — Dallas, Texas, United States
• NeoTX - 10312 — El Paso, Texas, United States
• NeoTX - 10310 — Tyler, Texas, United States
• NeoTX - 10311 — Fairfax, Virginia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.